

References

L-228

1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, et. Al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*. 2002;100(13):4325-36.
2. Patel JP, Gonen M, Figueroa ME, et al .Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1079-89.
3. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-18.
4. Morrissette JJ, Bagg A. Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. *Clin Lab Med*. 2011;31(4):659-86.
5. Ziai JM, Siddon AJ; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia. *Am J Clin Pathol*. 2015;144(4):539-54.
6. NCCN Clinical Practice Guidelines in Oncology, Guidelines for Treatment of Acute myeloid leukemia. Version 3.2017- June 6, 2017.
7. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at:
<http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>